CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation

Hisao Nagoshi; Kayo Toishigawa; Tomoko Inoue; Yoshiko Okikawa; Takahiko Miyama; Takakazu Kawase; Taro Edahiro; Kyoko Kazihara; Hiromi Nakagawa; Aiko Yamaoka; Mitsunori Noma; Teruhisa Fujii; Noriyasu Fukushima; Tatsuo Ichinohe

doi:10.1007/s12308-019-00383-7

CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation

Hisao Nagoshi, Kayo Toishigawa, Tomoko Inoue, Yoshiko Okikawa, Takahiko Miyama, Takakazu Kawase, Taro Edahiro, Kyoko Kazihara, Hiromi Nakagawa, Aiko Yamaoka, Mitsunori Noma, Teruhisa Fujii, Noriyasu Fukushima, Tatsuo Ichinohe

研究成果: ジャーナルへの寄稿 › Letter › 査読

本文言語	英語
ページ（範囲）	47-49
ページ数	3
ジャーナル	Journal of Hematopathology
巻	13
号	1
DOI	https://doi.org/10.1007/s12308-019-00383-7
出版ステータス	出版済み - 01-03-2020
外部発表	はい

All Science Journal Classification (ASJC) codes

病理学および法医学
組織学
血液学

文献へのアクセス

10.1007/s12308-019-00383-7

他のファイルとリンク

引用スタイル

Nagoshi, H., Toishigawa, K., Inoue, T., Okikawa, Y., Miyama, T., Kawase, T., Edahiro, T., Kazihara, K., Nakagawa, H., Yamaoka, A., Noma, M., Fujii, T., Fukushima, N., & Ichinohe, T. (2020). CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation. Journal of Hematopathology, 13(1), 47-49. https://doi.org/10.1007/s12308-019-00383-7

@article{6d97ae1aff0b4de6b224de341fbcfc8f,

title = "CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation",

author = "Hisao Nagoshi and Kayo Toishigawa and Tomoko Inoue and Yoshiko Okikawa and Takahiko Miyama and Takakazu Kawase and Taro Edahiro and Kyoko Kazihara and Hiromi Nakagawa and Aiko Yamaoka and Mitsunori Noma and Teruhisa Fujii and Noriyasu Fukushima and Tatsuo Ichinohe",

note = "Funding Information: All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent for writing and publishing this report was obtained from the patient included in the study. T. Ichinohe has received speaker honoraria from Bristol-Myers Squibb, Celgene, Janssen Pharmaceutical K.K., and Kyowa Kirin Co. and research funding from Astellas Pharma, Chugai Pharmaceutical Co., CSL Behring, Eisai Co., FUJIFILM Wako Chemicals., Kyowa Kirin Co., Ono Pharmaceutical Co., Pfizer, Nippon Shinyaku Co., MSD, Otsuka Pharmaceutical Co., Repertoire Genesis Inc., Sumitomo Dainippon Pharma Co., Taiho Pharmaceutical Co., Takara Bio Inc., Takeda Pharmaceutical Co., and Zenyaku Kogyo Co. All other authors declare that they have no conflict of interest. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Funding Information: This study was supported in part by Grants-in-Aid from the Japan Agency for Medical Research and Development (AMED) (no. 19ek05100023h0003 to TI), Grants-in-Aid for Young Scientists (JSPS KAKENHI no. JP18K15281 to HN) from the Japan Society for the Promotion of Science (JSPS), and the Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University (to TI). ",

year = "2020",

month = mar,

day = "1",

doi = "10.1007/s12308-019-00383-7",

language = "English",

volume = "13",

pages = "47--49",

journal = "Journal of Hematopathology",

issn = "1868-9256",

publisher = "Springer Verlag",

number = "1",

}

Nagoshi, H, Toishigawa, K, Inoue, T, Okikawa, Y, Miyama, T, Kawase, T, Edahiro, T, Kazihara, K, Nakagawa, H, Yamaoka, A, Noma, M, Fujii, T, Fukushima, N & Ichinohe, T 2020, 'CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation', Journal of Hematopathology, vol. 13, no. 1, pp. 47-49. https://doi.org/10.1007/s12308-019-00383-7

CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation. / Nagoshi, Hisao; Toishigawa, Kayo; Inoue, Tomoko その他.
In: Journal of Hematopathology, Vol. 13, No. 1, 01.03.2020, p. 47-49.

研究成果: ジャーナルへの寄稿 › Letter › 査読

TY - JOUR

T1 - CD56-positive B cell precursor acute lymphoblastic leukemia harboring KMT2A-AFF1 rearrangement developed in a pregnant woman successfully treated with allogeneic hematopoietic cell transplantation

AU - Nagoshi, Hisao

AU - Toishigawa, Kayo

AU - Inoue, Tomoko

AU - Okikawa, Yoshiko

AU - Miyama, Takahiko

AU - Kawase, Takakazu

AU - Edahiro, Taro

AU - Kazihara, Kyoko

AU - Nakagawa, Hiromi

AU - Yamaoka, Aiko

AU - Noma, Mitsunori

AU - Fujii, Teruhisa

AU - Fukushima, Noriyasu

AU - Ichinohe, Tatsuo

N1 - Funding Information: All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent for writing and publishing this report was obtained from the patient included in the study. T. Ichinohe has received speaker honoraria from Bristol-Myers Squibb, Celgene, Janssen Pharmaceutical K.K., and Kyowa Kirin Co. and research funding from Astellas Pharma, Chugai Pharmaceutical Co., CSL Behring, Eisai Co., FUJIFILM Wako Chemicals., Kyowa Kirin Co., Ono Pharmaceutical Co., Pfizer, Nippon Shinyaku Co., MSD, Otsuka Pharmaceutical Co., Repertoire Genesis Inc., Sumitomo Dainippon Pharma Co., Taiho Pharmaceutical Co., Takara Bio Inc., Takeda Pharmaceutical Co., and Zenyaku Kogyo Co. All other authors declare that they have no conflict of interest. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Funding Information: This study was supported in part by Grants-in-Aid from the Japan Agency for Medical Research and Development (AMED) (no. 19ek05100023h0003 to TI), Grants-in-Aid for Young Scientists (JSPS KAKENHI no. JP18K15281 to HN) from the Japan Society for the Promotion of Science (JSPS), and the Program of the network-type Joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University (to TI).

PY - 2020/3/1

Y1 - 2020/3/1

UR - http://www.scopus.com/inward/record.url?scp=85077572327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077572327&partnerID=8YFLogxK

U2 - 10.1007/s12308-019-00383-7

DO - 10.1007/s12308-019-00383-7

M3 - Letter

AN - SCOPUS:85077572327

SN - 1868-9256

VL - 13

SP - 47

EP - 49

JO - Journal of Hematopathology

JF - Journal of Hematopathology

IS - 1

ER -